Nomination Committe for IDL appointed | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

February 2019

Nomination Committe for IDL appointed

IDL Biotechs extra ordinary general meeting held on the 25th October 2018 decided to establish a nomination committee.

The two largest shareholders in terms of votes who wish to participate in the nomination committee were entitled to appoint one member each. The shareholders Leif Pihlqvist with companies and AB Grenspecialisten has appointed Jerker Swanstein and Jens Ismunden.

 

For more information, read the pressrelease here (in swedish)

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech

Skip this intro